Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status

Blood

Volumn 98, Issue 2, 2001, Pages 405-413

  Pallis, Monica ^a,b,c   Grundy, Martin ^a,b   Turzanski, Julie ^a,b   Kofler, Reinhard ^a,b   Russell, Nigel ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOBIMANE; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; DIAMIDE; DISULFIDE; DITHIOL DERIVATIVE; MALEIC ACID DIETHYL ESTER; MONOVALENT CATION; MULTIDRUG RESISTANCE PROTEIN; MUTANT PROTEIN; OXIDIZING AGENT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53; THIOL; THIOL DERIVATIVE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; CANCER CHEMOTHERAPY; CELL HETEROGENEITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS LINKING; CYTOMETRY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPERATURE DEPENDENCE; WILD TYPE;

EID: 0035880254     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.2.405     Document Type: Article

References (79)

1. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323-3329.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
3. Leith C. Multidrug resistance in leukemia. Curr Opin Hematol. 1998;5:287-291.
4. Kroemer G. The proto-oncogene bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3:614-620.
5. Reed JC. Bcl-2 family proteins. Oncogene. 1998;17:3225-3236.
6. Keith FJ, Bradbury DA, Zhu Y-M, Russell NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia. 1995;9:131-138.
7. Konopleva M, Tari AM, Estrov Z, et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000;95:3929-3938.
8. Lauria F, Raspadori D, Rondelli D, et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia. 1997;11:2075-2078.
9. Porwitt-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukaemia. Leukaemia. 1995;9:1191-1198.
10. Lohri A, van Hille B, Bacchi M, et al. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase II α) in 57 newly diagnosed acute myeloid leukaemias. Eur J Haematol. 1997;59:206-215.
11. Andreeff M, Zhao S, Konopleva M, et al. The role of Bcl-2 apoptosis regulating genes in acute myeloid leukemia (AML). Blood. 1997;90:66a.
12. Kaufmann SH, Karp JE, Svingen PA, et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 1998;91:991-1000.
13. Andreeff M, Jiang S, Zhang X, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881-1892.
14. Hall AG. Review: the role of glutathione in the regulation of apoptosis. Eur J Clin Invest. 1999;29:238-245.
15. Kearns P, Pieters R, Rottier MM, et al. Glutathione in childhood acute leukaemias. Adv Exp Med Biol. 1999;457:211-216.
16. Tidefelt U, Elmhorn-Rosenborg A, Paul C, Hao X, Mannervik B, Eriksson L. Expression of glutathione transferase π as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia. Cancer Res. 1992;52:3281-3285.
17. Sato N, Iwata S, Nakamura K, Hori T, Mori K, Yodoi J. Thiol-mediated redox regulation of apoptosis: possible roles of cellular thiols other than glutathione in T cell apoptosis. J Immunol. 1995;154:3194-3203.
18. Wang J, Kobayashi M, Sakurada K, Imamura M, Moriuchi T, Hosokawa M. Possible roles of an adult T-cell leukemia (ATL)-derived factor/thioredoxin in the drug resistance of ATL to Adriamycin. Blood. 1997;89:2480-2487.
19. Saitoh M, Nishitoh H, Fujii M, etal. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998;17:2596-2606.
20. Wattel E, Preudhomme C, Hecquet B, et al. P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994;84:3148-3157.
21. Geley S, Hartmann BL, Hattmannstorfer R, et al. p53-induced apoptosis in the human T-ALL cell line CCRF-CEM. Oncogene. 1997;15:2429-2437.
22. Lee JM. Inhibition of p53-dependent apoptosis by the KIT tyrosine kinase: regulation of mitochondrial permeability transition and reactive oxygen species generation. Oncogene. 1998;17:1653-1662.
23. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997;389:300-305.
24. Gladyshev VN, Factor VM, Housseau F, Hatfield DL. Contrasting patterns of regulation of the antioxidant selenoproteins, thioredoxin reductase, and glutathione peroxidase in cancer cells. Biochem Biophys Res Commun. 1998;251:488-493.
25. Wang Q, Beck WT. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res. 1998;58:5762-5769.
26. Decaudin D, Matzo I, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy. Int J Oncol. 1998;12:141-152.
27. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta. 1995;1241:139-176.
28. Zamzami N, Susin SA, Marchetti P, et al. Mitochondrial control of nuclear apoptosis. J Exp Med. 1996;183:1533-1544.
29. Petit PX, Zamzami N, Vayssiere JL, Mignotte B, Kroemer G, Castedo M. Implication of mitochondria in apoptosis. Mol Cell Biochem. 1997;174:185-188.
30. Newmeyer D, Farschon D, Reed J. Cell-free apoptosis in xenopus egg extracts: inhibition by bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell. 1994;79:353-364.
31. Susin S, Zamzami N, Kroemer K. The cell biology of apoptosis: evidence for the implication of mitochondria. Apoptosis. 1996;1:231-242.
32. Petronilli V, Cola C, Massari S, Colonna R, Bernardi P. Physiological effectors modify voltage sensing by the cyclosporin A-sensitive permeability transition pore of mitochondria. J Biol Chem. 1993;268:21939-21945.
33. Petronilli V, Costantini P, Scorrano L, Colonna R, Passamonti S, Bernardi P. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols: increase of the gating potential by oxidants and its reversal by reducing agents. J Biol Chem. 1994;269:16638-16642.
34. Costantini P, Chernyak BV, Petronilli V, Bernardi P. Selective inhibition of the mitochondrial permeability transition pore at the oxidation-reduction sensitive dithiol by monobromobimane. FEBS Lett. 1995;362:239-242.
35. Marchetti P, Castedo M, Susin SA, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med. 1996;184:1155-1160.
36. Xiang JL, Chao DT, Korsmeyer SJ. Bax-induced cell-death may not require interleukin 1-beta-converting enzyme-like proteases. Proc Natl Acad Sci U S A. 1996;93:14559-14563.
37. Susin S, Zamzami N, Castedo M, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med. 1996;184:1331-1341.
38. Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 1998;281:2027-2031.
39. Shimizu S, Eguchi Y, Kamiike W, et al. Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. Proc Natl Acad Sci U S A. 1998;95:1455-1459.
40. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 1999;399:483-487.
41. Plasek J, Sigler K. Slow fluorescent indicators of membrane potential: a survey of different approaches to probe response analysis. J Photochem Photobiol B. 1996;33:101-124.
42. L is heterogeneously expressed by acute myeloblastic leukemia cells and is associated with autonomous growth in vitro and with p-glycoprotein expression. Leukemia. 1997;11:945-949.
43. Pallis M, Turzanski J, Langabeer S, Russell NH. Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts. Adv Exp Med Biol. 1999;457:77-88.
44. Philpott N, Turner A, Scopes J, et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood. 1996;87:2244-2251.
45. Pallis M, Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelinceramide apoptotic pathway. Blood. 2000;95:2897-2904.
46. Zhu YM, Das-Gupta EP, Russell NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood. 1999;94:733-740.
47. Marchetti P, Decaudin D, Macho A, et al. Redox regulation of apoptosis: impact of thiol oxidation status on mitochondrial function. Eur J Immunol. 1997;27:289-296.
48. 3 or rhodamine 123, is a reliable fluorescent probe to assess δ ψ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett. 1997;411:77-82.
49. L prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Mol Cell. 1999;3:159-167.
50. Hunter AE, Rogers SY, Roberts IA, Barrett AJ, Russell N. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood. 1993;82:899-903.
51. Miyauchi J, Kelleher CA, Yang YC, et al. The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood. 1987;70:657-663.
52. Decaudin D, Geley S, Hirsch T, et al. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res. 1997;57:62-67.
53. L regulates the membrane potential and volume homeostasis of mitochondria. Cell. 1997;91:627-637.
54. Tan M, Li S, Swaroop M, Guan K, Oberley LW, Sun Y. Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem. 1999;274:12061-12066.
55. Turzanski J, Pallis M, Russell N. Comments on: multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer: mutant p53 and high expression of MRP are associated in acute myeloblastic leukaemia [letter]. Eur J Cancer. 2000;36:270-272.
56. Rappa G, Finch RA, Sartorelli AC, Lorico A. New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models. Biochem Pharmacol. 1999;58:557-562.
57. van der Kolk DM, Vellenga E, Muller M, de Vries EG. Multidrug resistance protein MRP1, glutathione, and related enzymes: their importance in acute myeloid leukemia. Adv Exp Med Biol. 1999;457:187-198.
58. Chernyak BV, Bernardi P. The mitochondrial permeability transition pore is modulated by oxidative agents through both pyridine nucleotides and glutathione at two separate sites. Eur J Biochem. 1996;238:623-630.
59. Chernyak BV. Redox regulation of the mitochondrial permeability transition pore. Biosci Rep. 1997;17:293-302.
60. Costantini P, Chernyak BV, Petronilli V, Bernardi P. Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J Biol Chem. 1996;271:6746-6751.
61. Meister A. Mitochondrial changes associated with glutathione deficiency. Biochim Biophys Acta. 1995;1271:35-42.
62. Bump EA, Yu NY, Brown JM. The use of drugs which deplete intracellular glutathione in hypoxic cell radiosensitization. Int J Radiat Oncol Biol Phys. 1982;8:439-442.
63. Mirkovic N, Voehringer DW, Story MD, McConkey DJ, McDonnell TJ, Meyn RE. Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene. 1997;15:1461-1470.
64. Fernandes RS, Cotter TG. Apoptosis or necrosis: intracellular levels of glutathione influence mode of cell death. Biochem Pharmacol. 1994;48:675-681.
65. Ueda S, Nakamura H, Masutani H, et al. Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c. J Immunol. 1998;161:6689-6695.
66. El-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol. 1998;8:345-357.
67. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 1998;292:435-445.
68. Li PF, Dietz R, von Harsdorf R. P53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J. 1999;18:6027-6036.
69. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T. Reactive oxygen species are down-stream mediators of p53-dependent apoptosis. Proc Natl Acad Sci U S A. 1996;93:11848-11852.
70. Halestrap AP, Woodfield KY, Connern CP. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J Biol Chem. 1997;272:3346-3354.
71. Costantini P, Belzacq AS, Vieira HL, et al. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene. 2000;19:307-314.
72. Zamzami N, Marchetti P, Castedo M, et al. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett. 1996;384:53-57.
73. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 1997;34:9-19.
74. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;75:241-251.
75. Zamzami N, Marzo I, Susin SA, et al. The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition. Oncogene. 1998;16:1055-1063.
76. Ishikawa T, Bao JJ, Yamane Y, et al. Coordinated induction of MRP/GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem. 1996;271:14981-14988.
77. Kuo MT, Bao J, Furuichi M, et al. Frequent coexpression of MRP/GS-X pump and γ-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochem Pharmacol. 1998;55:605-615.
78. Bradbury DA, Russell NH. Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br J Haematol. 1995;91:374-379.
79. Sargent JM, Williamson C, Hall AG, Elgie AW, Taylor CG. Evidence for the involvement of the glutathione pathway in drug resistance in AML. Adv Exp Med Biol. 1999;457:205-209.